Both in the context of exclusively dietary interventions and after bariatric surgery or treatment with GLP(glucagon-like peptide)-1 analogs, there is not only a reduction in weight, but also a loss of muscle mass to varying degrees. A differentiated clinical examination shows that this loss does not necessarily equate to a functional deterioration.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- SURPASS-CVOT
Tirzepatide versus Dulaglutide in T2D with ASCVD
- Secondary prevention after ACS: individually optimized lipid management
Trend towards early combination therapy and new strategies for lowering Lp(a)
- Pediatric Brain Tumors
Psychiatry versus Neuro-Oncology: Diagnostic Pitfalls
- What the latest studies on the entire EF spectrum mean for clinical practice
Heart Failure – The 2026 Evidence Update
- Acute ischemic stroke
Alteplase and Tenecteplase Are on the Same Level
- CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment
SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes
- Wearables: screening via smartwatch?